Institute of Biological Engineering Wyss at Harvard University and the School of Engineering and Applied Sciences, Harvard University, John A. Paulson (SEAS) announced today that Novartis will have access to the commercial development of its therapeutic based on biomaterials, cancer vaccine technology, immunity against cancer. In accordance with the license agreement, headed the development of Harvard technologies (OTD), Novartis will have the worldwide rights to the target application for the development and transfer of this approach to treating patients.
Unlike cancer cell immunoterapevtov that rely on manipulation of immune cells in vitro and their transfer in patients implantable approach to an immunological material activates endogenous immune cells within the body to launch an attack on the cancer patient. The new technique was developed, incubated and promoted in the Wyss Institute and SEAS David Mooney, a member of the Faculty Core Wyss, head of the Immuno-Materials Initiative Wyss Institute and a professor of bioengineering at SEAS Robert Pinkas.
Treatment will pass through the porous frame material made of the commonly used biodegradable medical polymer filled with inactivated antigens from tumor cells of a patient, and immunostimulatory molecules that attract dendritic cells of the immune system to the site of immunological material, and activated to stimulate the host response. After the activation of dendritic cells are located to nearby lymph nodes for the organization of anti-tumor responses throughout the body.
"This work was the result of remarkable interdisciplinary efforts with combined experience bioengineers, biologists and immunologists - Mooney said." We have demonstrated that these biomaterials can be easily delivered to patients, bypass the need for modification is the body's cells. This concept led to the creation of a very promising platform for cancer immunotherapy. "
In 2013, the Institute and the Wyss Institute for Cancer Dana-Farber (DFCI) initiated a phase I clinical trials in DFCI to test the safety of the first of these implantable cancer vaccine based on immune material in patients with melanoma, a lethal form of skin cancer. The process, led by F. Stephen Hodi, Jr., MD, director of the Melanoma Center DFCI and professor of medicine at Harvard Medical School (HMS), still continues with many of his original patients.
Team demonstrated that cancer vaccine may potentially destroy various types of tumors, in addition to the preventive protection in different animal models.
Novartis has established a cooperation agreement with the Wyss Institute for the further development of biomaterials systems to its portfolio of immuno-oncology methods for the second generation.